Immunomodulators are drugs, biological agents, or therapies that adjust how the immune system behaves. Some ramp it up to fight cancer or infection. Others dial it down to prevent organ rejection or quiet autoimmune diseases. A few do both depending on context, shifting the immune response rather than simply boosting or suppressing it. The term covers an enormous range of treatments, from century-old bacterial extracts to gene-engineered cell therapies approved in the last decade, and understanding the landscape helps make sense of how modern medicine manages diseases rooted in immune dysfunction.
Stimulating the Immune System
When the goal is to strengthen or sharpen an immune response, immunostimulants are the tool. The most familiar examples are vaccines. Every vaccine works, in part, by presenting the immune system with something it should learn to recognize. Adjuvants, the helper ingredients mixed into many vaccines, push innate immune responses that in turn shape stronger, longer-lasting adaptive immunity. They do this by activating receptors and signaling pathways that tell the body a genuine threat is present, which amplifies the response to the vaccine antigen itself.1PubMed Central. Vaccine adjuvants: putting innate immunity to work
Beyond vaccines, cytokines have been used as direct immunostimulants in cancer treatment. Interferon alpha is approved for high-risk melanoma and several other cancers, while high-dose interleukin-2 is approved for metastatic kidney cancer and melanoma. Both were among the earliest immunotherapy drugs, though their use has declined as newer agents have become available.2Europe PMC. Cytokines in the Treatment of Cancer Other cytokines like GM-CSF, interferon gamma, and several interleukins have been tested in clinical trials and remain part of ongoing research.3Europe PMC. Cytokines in the Treatment of Cancer
Suppressing the Immune System
On the opposite end of the spectrum, immunosuppressants are used when the immune system is causing harm, either by attacking the body’s own tissues in autoimmune diseases or by rejecting a transplanted organ. Corticosteroids like prednisone are the workhorses of broad immunosuppression, dampening inflammation across multiple pathways at once. They remain a first-line treatment for acute flares of many autoimmune conditions, though their long-term side effects (weight gain, bone thinning, elevated blood sugar) make them a poor choice for indefinite use.
For transplant recipients and patients with severe autoimmune disease, calcineurin inhibitors are a cornerstone of therapy. Cyclosporine and tacrolimus work by blocking a specific enzyme called calcineurin, which prevents the activation of T cells, the immune cells that would otherwise attack a transplanted organ or inflamed tissue. Newer derivatives like voclosporin have been developed along similar principles.4PubMed. Calcineurin Inhibitors: Current Role, Toxicity Management, and Future Frontiers in Immunosuppression These drugs are effective but require careful dosing because too much suppression leaves the patient vulnerable to infections, while too little risks rejection or disease flare.
Targeted Biologics
One of the biggest shifts in immunomodulation over the past two decades has been the move from broad suppression toward precision. Instead of dampening the entire immune system, targeted biologics block specific molecules involved in disease.
TNF-alpha inhibitors are a prime example. Tumor necrosis factor alpha is a signaling protein that drives inflammation in conditions like rheumatoid arthritis and inflammatory bowel disease. Five TNF-alpha antagonists, including infliximab, etanercept, adalimumab, golimumab, and certolizumab pegol, are widely used and are roughly equally effective for rheumatoid arthritis despite having somewhat different molecular structures.5PubMed. Molecular mechanisms of action of anti-TNF-α agents – Comparison among therapeutic TNF-α antagonists These drugs transformed the treatment of rheumatoid arthritis by offering patients a way to target the root inflammatory process rather than just masking symptoms with painkillers or steroids.6PubMed Central. TNF inhibitor therapy for rheumatoid arthritis
Adalimumab, marketed as Humira, became one of the best-selling drugs in pharmaceutical history, which says something about how many people live with conditions driven by TNF-alpha. The arrival of biosimilars, biologic medicines with no clinically meaningful differences in safety or efficacy from the original, has begun to expand access and drive prices down, though the manufacturing complexity of biologics means they remain expensive compared to traditional pills.7PubMed Central. The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases
Checkpoint Inhibitors in Cancer
Cancer cells are remarkably good at hiding from the immune system. They exploit natural “checkpoint” pathways, proteins like PD-1 and CTLA-4, that normally prevent immune cells from attacking the body’s own tissue. By co-opting these off-switches, tumors effectively tell T cells to stand down.
Immune checkpoint inhibitors block those interactions, releasing the brakes on T cells so they can recognize and attack tumors. Drugs targeting PD-1, its ligand PD-L1, and CTLA-4 have improved survival across multiple advanced cancers and are now used as both single agents and in combination regimens.8PubMed Central. Overview of Checkpoint Inhibitors Mechanism of Action: Role of Immune-Related Adverse Events and Their Treatment on Progression of Underlying Cancer The rapid expansion of checkpoint inhibitor use means more patients are living longer, but it also means more patients are experiencing a particular set of side effects called immune-related adverse events.
These adverse events can affect almost any organ, from the skin and gut to the liver, lungs, and endocrine glands. They arise precisely because the drug is doing its job: by unleashing the immune system against cancer, it sometimes unleashes it against healthy tissue too. The mechanisms behind these reactions remain incompletely understood, and managing them without undermining the cancer treatment is a significant clinical challenge.9PubMed Central. Immune-related adverse events of immune checkpoint inhibitors: a review
Engineered Cell Therapies
Some of the most dramatic developments in immunomodulation involve engineering a patient’s own immune cells. CAR-T cell therapy takes T cells from a patient’s blood, genetically modifies them in a lab to express receptors that recognize a specific tumor antigen, and then infuses them back into the patient. These engineered cells can seek out and destroy cancer cells that the unmodified immune system was ignoring.10PubMed. CAR T cell therapy: A new era for cancer treatment CAR-T therapy has shown remarkable success in certain blood cancers, and its development represents one of the most personalized forms of medicine available.11PubMed Central. The evolution of cancer immunotherapy: a comprehensive review of its history and current perspectives
A related approach uses bispecific T-cell engagers, molecules designed to physically bridge a T cell and a tumor cell. One end binds a protein on the T cell’s surface, the other binds a tumor-associated antigen, pulling the two cells together and triggering the T cell to kill the tumor cell.12PubMed Central. Bispecific T-cell engagers for cancer immunotherapy These molecules activate T cells directly at the tumor site without requiring the weeks-long manufacturing process that CAR-T therapy demands.13PubMed Central. T-Cell Engagers-The Structure and Functional Principle and Application in Hematological Malignancies
Small Molecules That Reshape Immune Signaling
Not all immunomodulators are large biologic proteins. Small molecule drugs, traditional pills that can be taken by mouth, have carved out a significant role. JAK inhibitors, for instance, block enzymes called Janus kinases that relay signals from cytokines into cells. By interrupting these signaling cascades, JAK inhibitors reduce the inflammatory response in conditions like rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. Their development confirmed that targeting specific points inside immune cells could work as well as, or alongside, the biologic approach of blocking signals outside the cell.14PubMed Central. Small molecules to the rescue: Inhibition of cytokine signaling in immune-mediated diseases
Then there are the immunomodulatory drugs (IMiDs) like lenalidomide and pomalidomide, which are used primarily in blood cancers such as multiple myeloma. These drugs have a fascinating mechanism: they bind to a protein called cereblon and cause it to tag certain transcription factors for destruction. When those factors are degraded, T cells become activated, and the cancer-supporting environment shifts.15PubMed Central. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.) Resistance can develop when cancer cells alter the cereblon pathway, which remains an active area of research.16Blood. Cereblon (CRBN) Splice Isoform Lacking Exon 10 Attenuates Lenalidomide-Mediated Degradation of Aiolos and Is Upregulated in Immunomodulatory Drugs (IMiDs) Resistant Myeloma (MM) Patients IMiDs sit in an interesting category: they simultaneously suppress tumor growth and stimulate immune activity, which is why the broader label “immunomodulator” fits them better than either “stimulant” or “suppressant.”
The Body’s Own Immunomodulators
Your body already runs a sophisticated immunomodulation program without any drugs. Endogenous glucocorticoids, primarily cortisol, are hormones released during stress that regulate inflammation, metabolism, and immune cell behavior. Decades of research have defined how the endocrine stress response interfaces with the immune system, and synthetic versions of these hormones (like prednisone and dexamethasone) remain among the most widely prescribed anti-inflammatory drugs in medicine.17PubMed Central. Immune regulation by glucocorticoids
The gut microbiome is another powerful endogenous immunomodulator. Bacteria in the intestines ferment dietary fiber into short-chain fatty acids, which influence the behavior and fate of immune cells throughout the body. These metabolites affect both the innate immune system and the adaptive side, including T-cell subsets, B cells, and plasma cells.18PubMed Central. Regulation of short-chain fatty acids in the immune system This is why researchers are increasingly interested in diet, probiotics, and fiber intake as factors that shape immune health, though translating that interest into precise clinical recommendations is still a work in progress.
Natural compounds from food sources also have immunomodulatory properties. Beta-glucans, found in oats, barley, mushrooms, and yeast, function as biological response modifiers. They promote the maturation of dendritic cells, stimulate cytokine secretion, and help regulate adaptive immune responses through specific receptors on immune cells.19PubMed Central. Immunomodulatory Effect and Biological Significance of β-Glucans These effects are real and documented, but they are modest compared to pharmaceutical immunomodulators. Eating oatmeal will not replace a checkpoint inhibitor. Still, the research suggests that dietary patterns genuinely shape baseline immune function over time.
The Infection Trade-Off
The fundamental tension in immunosuppressive therapy is that reducing immune activity to prevent one problem, whether organ rejection, autoimmune damage, or graft-versus-host disease, creates vulnerability to infections. Transplant medicine uses the concept of a “net state of immunosuppression” to capture the total burden of all factors contributing to infection risk, not just the drugs themselves but also co-infections, nutritional status, and individual biology. One practical way to gauge how suppressed a patient’s immune system has become is to measure viral loads for latent viruses: if the body can no longer keep common viruses in check, the overall level of suppression is likely high.20Oxford Academic (Clin Infect Dis). Immunosuppressive Agents and Infectious Risk in Transplantation: Managing the “Net State of Immunosuppression”
For patients on biologic immunomodulators like TNF inhibitors or checkpoint inhibitors, infection risk is more nuanced. TNF inhibitors increase susceptibility to certain opportunistic infections, particularly tuberculosis, because TNF-alpha plays a key role in containing latent TB. That is why screening for TB before starting these drugs is standard practice. Checkpoint inhibitors, by contrast, unleash the immune system rather than suppressing it, so their infection profile is different. The bigger concern there is the autoimmune-like reactions already described.
Monitoring and Dose Optimization
Many immunomodulators have narrow therapeutic windows. Too little drug and the disease is uncontrolled; too much and side effects become unacceptable. Therapeutic drug monitoring, measuring drug concentrations in the blood and adjusting doses accordingly, has become a key strategy, especially for biologic therapies used in inflammatory bowel disease. Clinicians need to interpret drug levels alongside the patient’s inflammatory status, the drug’s behavior in the body, the risk of the patient developing antibodies against the drug, and the specific treatment goals.21PubMed Central. A Practical Guide to Therapeutic Drug Monitoring of Biologic Medications for Inflammatory Bowel Disease
One particular challenge is immunogenicity: the body sometimes produces antibodies against biologic drugs, effectively neutralizing them. When this happens, drug levels drop and the patient loses response. Detecting this early through monitoring allows the clinician to switch therapies or adjust doses before the patient has a full disease flare. Future approaches will likely incorporate better pharmacokinetic modeling and even genetic profiling to predict how individual patients will handle specific drugs.22PubMed Central. Challenges in Therapeutic Drug Monitoring: Optimizing Biological Treatments in Patients With Inflammatory Bowel Disease and Other Immune-Mediated Inflammatory Diseases
Age and Immune Response
How well immunomodulators work depends partly on how old the immune system is. Aging brings immunosenescence, a gradual decline in immune function that raises disease risk and can reduce the effectiveness of treatments. In older adults, vaccines produce weaker responses, cancer immunotherapy works less predictably, and the balance between immune surveillance and autoimmunity shifts.23PubMed. Immunosenescence: Shaping the Hematological Narrative in the Era of Aging
Complicating this picture is cytomegalovirus (CMV), a common virus that persistently infects a large share of the global population. Interestingly, CMV appears to improve immune function in younger people, acting as a kind of training partner for the immune system. In older people, though, the relationship may flip. The excess mortality seen in CMV-positive elderly cohorts seems to be driven more by vascular disease than by immune collapse, but the interaction between CMV, age, and co-morbidities makes it a significant variable when planning immunomodulatory therapy for older patients.24PubMed. ‘From immunosenescence to immune modulation’: a re-appraisal of the role of cytomegalovirus as major regulator of human immune function
From Bacterial Toxins to mRNA Platforms
The history of immunomodulation in cancer stretches back over a century. In 1891, William Coley injected streptococcal bacteria into a patient with inoperable cancer, reasoning that the resulting infection might trigger the immune system to attack the tumor. It worked, and over the next four decades he treated more than a thousand cancer patients with bacterial products that became known as Coley’s Toxins, reporting strong results in bone and soft-tissue sarcomas.25PubMed Central. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas His work drew heavy skepticism, and the rise of radiation and chemotherapy pushed it aside. But modern immunology has vindicated his core insight: the immune system can be harnessed against cancer.26PubMed Central. Talkin’ Toxins: From Coley’s to Modern Cancer Immunotherapy
The mid-twentieth century brought cytokine therapies like interferons and interleukins, which showed that manipulating the immune response could shrink tumors. Then came the discoveries of immune checkpoints and the development of checkpoint inhibitors. Most recently, CAR-T cell therapy has achieved remarkable success in certain blood cancers, representing perhaps the most personalized treatment medicine has ever produced.27PubMed Central. The evolution of cancer immunotherapy: a comprehensive review of its history and current perspectives
The frontier is still moving. mRNA vaccine technology, familiar to most people from COVID-19 shots, is being adapted for cancer. These vaccines deliver tumor antigens to immune cells, training them to recognize and attack cancer. The same mRNA platform can also encode immunomodulatory proteins like costimulatory ligands and receptor targets, giving researchers a flexible tool to tune the immune response with a single injection.28PubMed Central. mRNA vaccine in cancer therapy: Current advance and future outlook Whether mRNA cancer vaccines will achieve the widespread success of checkpoint inhibitors remains to be seen, but the platform’s speed and adaptability make it one of the most watched areas in immunomodulation research today.
Biosimilars and the Access Problem
The effectiveness of biologic immunomodulators is well established, but their cost has always been a barrier. Manufacturing a biologic is far more complex than synthesizing a traditional small-molecule drug. These are large protein molecules produced in living cell systems, requiring precise conditions and extensive quality control. That complexity keeps prices high and, until recently, kept competition low because patent protections prevented alternatives from entering the market.
Biosimilars are changing this dynamic. These are biologic medicines that have been shown to have no clinically meaningful differences from the original product in terms of safety and efficacy. Their entry into the market creates competition that can lower costs and expand access, which matters for the millions of people worldwide who need long-term biologic therapy for conditions like rheumatoid arthritis, psoriasis, and Crohn’s disease.29PubMed Central. The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases Developers face the challenge of operating efficiently enough to keep prices competitive without cutting corners on product quality, supply chain reliability, or long-term safety monitoring. For patients, the practical question is often whether their insurance covers the biosimilar or the originator, and whether switching between them is safe. The evidence so far suggests that switching is generally well tolerated, but the conversation between patient and doctor still matters.